Skip to content

XIENCE PRIME 1011734-33Recalls & reported problems

Abbott Vascular Inc. · XIENCE PRIME LL Everolimus Eluting Coronary Stent System 3.50 mm x 33 mm / Rapid-Exchange · Class 3 · Implant

Data updated Oct 16, 2026 from official FDA records · Editorial policy

Adverse event reports
1
Deaths reported
0
Injuries reported
1
Recalls naming it
0

Summary

The FDA's MAUDE database contains 1 adverse event report that list this exact device (DI 08717648177262), received between Nov 7, 2016 and Nov 7, 2016 — classified as 1 injury.

Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 16, 2026.

Most reported problems

Device problems

  • Adverse Event Without Identified Device or Use Problem1

Patient problems

  • Stenosis1

Recent adverse event reports

The 1 most recent of 1 reports, in the reporter's own words as published by the FDA.

  • InjuryNov 7, 2016Adverse Event Without Identified Device or Use Problem

    IT WAS REPORTED THAT ON (B)(6) 2013, THE PATIENT PRESENTED WITH SILENT ISCHEMIA. A 3.0X33MM XIENCE PRIME STENT WAS IMPLANTED IN THE MID RIGHT CORONARY ARTERY (RCA) LESION AND A 3.5X33MM XIENCE PRIME STENT WAS IMPLANTED IN THE PROXIMAL RCA. ON (B)(6) 2016, IN-STENT RESTENOSIS OF THE PROXIMAL RCA, 3.5X33MM XIENCE PRIME STENT WAS NOTED. ON (B)(6) 2016, AN ATHERECTOMY AND BALLOON ANGIOPLASTY WAS PERFORMED AS TREATMENT. THE PATIENTS CONDITION IMPROVED. THERE WAS NO ADDITIONAL INFORMATION PROVIDED.

    Patient problems: Stenosis

    MAUDE report 6084223 ↗

Other Coronary drug-eluting stent devices

All Coronary drug-eluting stent devices →

Sources and updates

How reports and recalls are matched · Editorial policy · Report an error on this page